A Study of MHB048C in Patients With Advanced Solid Tumors
NCT07192120
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
200
Enrollment
INDUSTRY
Sponsor class
Conditions
mCRPC (Metastatic Castration-resistant Prostate Cancer)
Advanced Malignant Solid Tumor
Interventions
DRUG:
MHB048C for Injection
Sponsor
Minghui Pharmaceutical (Hangzhou) Ltd